Increlex (mecasermin)

pCPA File Number: 21738
Negotiation Status:
Active Negotiation
Indication(s):
severe primary insulin-like growth factor-1 deficiency
Sponsor/Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
CADTH Project Number:
SR0692
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable